The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
An update on the diagnosis and treatment of Parkinson disease
Open accessAbstract
Parkinson disease is the second most common neurodegenerative disorder after Alzheimer disease.[1][1] Parkinson disease typically develops between the ages of 55 and 65 years and occurs in 1%–2% of people over the age of 60 years, rising to 3.5% at age 85–89 years.[2][2]–[4][3] About 0.3% of
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Parallel organization of functionally segregated circuits linking basal ganglia and cortex
Alexander, G. E., DeLong, M. R., & Strick, P. L. (1986) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.09.030186.002041 · Cited by 8,527
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Weaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Neurostimulation for Parkinson's Disease with Early Motor Complications
Schuepbach, W. M. M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Hälbig, T. D., Hesekamp, H., Navarro, S. M., Meier, N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205158 · Cited by 1,430
Cited by
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00356 · Cited by 437
Biomedical Applications and Bioavailability of Curcumin—An Updated Overview
Sohn, S.-I., Priya, A., Balasubramaniam, B., Muthuramalingam, P., Sivasankar, C., Selvaraj, A., Valliammai, A., Jothi, R., & Pandian, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122102 · Cited by 305
Clinical Features of Parkinson’s Disease: The Evolution of Critical Symptoms
Váradi, C. (2020) · Biology · doi:10.3390/biology9050103 · Cited by 196
Loh, H. W., Ooi, C. P., Palmer, E., Barua, P. D., Dogan, S., Tuncer, T., Baygin, M., & Acharya, U. R. (2021) · Electronics · doi:10.3390/electronics10141740 · Cited by 144
“…criteria of bradykinesia with at least one feature of rest tremor or rigidity, symptoms closely linked to dopaminergic neurons, and the absence of certain exclusion criteria and presence of supportive criteria, the main being a clear and dramatic beneficial response to dopaminergic therapy [15,16].”
BackgroundTargeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110
Amin, R., Quispe, C., Docea, A. O., Ydyrys, A., Kulbayeva, M., Durna Daştan, S., Calina, D., & Sharifi-Rad, J. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105376 · Cited by 74
A Review on Wearable Technologies for Tremor Suppression
Lora-Millan, J. S., Delgado-Oleas, G., Benito-León, J., & Rocon, E. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.700600 · Cited by 62
Signal Transduction Pathways of Acupuncture for Treating Some Nervous System Diseases.
Lai, H.-C., Chang, Q.-Y., & Hsieh, C.-L. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2909632 · Cited by 55
Metadata
- Authors
- Rizek, P., Kumar, N., & Jog, M. S.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Impact Inc.
- Published
- 2016-05-24
- Volume
- 188
- Issue
- 16
- Pages
- 1157-1165
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2403629665
- Cited by
- 447
- References
- 117
- FWCI
- 11.37
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.